摘要
[目的]评价以VDB为主的MVP方案治疗非小细胞肺癌（NSCIC）的疗效和毒副反应。[方法]每一病人给予2周期MVP方案进行化疗，每周期用VDB3mg/m2静注第1、8天；DDP30mg/m2静滴第1－3天；MMC6mg/m2静注第1天。[结果]3例完全缓解，8例部分缓解，总有效率52．38%。不同病期之间、不同组织类型之间的疗效差别无显著性差异（P＞0．05）。本方案主要毒副反应为骨髓抑制。[结论]MVP方案对NSCLC疗效是好的，其骨髓抑制的毒副作用应引起重视。
[Purpose]To evaluate the curative effcet and the side effect on treatment if NSCLC with MVP regiment.[Method]chemotherapy of2 cycles with MVP scheme was given to every patient.VDS was given on the first day and the eighth day (3mg/m2/every time intravenousinjection);DDP was given for the first day to the third day (30mg/daily intravenous drip); MMC w given on the first day (6mg/m2intwenous injection). That's all for one cycle. [ Result]Three cases achieved CR,8,casce PR.The overall response rate waw 52.38% There was nosignificant statistical difference among each stage of disease,and each different histological type (P >0.05). The major side ettec wasmyelosuppression.[Conclusions]MVP chemotherapy regimen dsve for NSCLC. But its side effect of myelosuppression must be paid ettention to.
